BioXcel Therapeutics (BTAI) Income towards Parent Company (2017 - 2026)

BioXcel Therapeutics' Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$13.7 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 0.76% year-over-year to -$13.7 million; the TTM figure through Mar 2026 stood at -$65.9 million (up 0.85% YoY), while the FY2025 annual figure was -$66.4 million, up 16.3% from the prior year.
• Income towards Parent Company was -$13.7 million for Q1 2026 at BioXcel Therapeutics, up from -$14.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$13.7 million in Q1 2026 to a low of -$54.9 million in Q4 2022.
• Historically, Income towards Parent Company has averaged -$29.6 million across 5 years, with a median of -$22.1 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company slumped 110.29% in 2022, then jumped 63.14% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$54.9 million in 2022, then soared by 59.8% to -$22.1 million in 2023, then jumped by 36.82% to -$13.9 million in 2024, then declined by 3.03% to -$14.4 million in 2025, then advanced by 4.52% to -$13.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$13.7 million (Q1 2026), -$14.4 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.